Showing 5,803 results

Filters Content type: News, Editors' picks Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Treatment outcomes & life expectancy

US: Among people with HIV, Black women have highest rate of premature death

Editor's pick
Healio
4 October 2021
PrEP science

Most switches to Descovy PrEP are probably unnecessary and some may be harmful

News
1 October 2021
Injectable & long-acting HIV treatment

Shionogi licenses out 3rd-gen HIV asset to ViiV

Editor's pick
FierceBiotech
28 September 2021
HIV treatment

Two thirds of HIV controllers in French cohort haven’t needed HIV treatment yet

News
28 September 2021
Drug interactions & pharmacokinetics

No Drop in Rate of Drug-Drug & Interactions With HIV Drugs Since 1985

Editor's pick
NATAP
27 September 2021
Bad science & bogus treatments

AIDS Misinformation and Failed Policies in Georgia

Editor's pick
TheBody
27 September 2021
Bad science & bogus treatments

Dear Governor Kemp: There Is No AIDS Vaccine

Editor's pick
POZ
22 September 2021
Injectable & long-acting HIV treatment

Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study

Editor's pick
GlobeNewswire
22 September 2021
Kidney problems

People over 50 years old or with existing kidney dysfunction are more likely to get kidney damage when using tenofovir disoproxil-based PrEP

News
21 September 2021
New & experimental HIV treatments

Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV

Editor's pick
GlobeNewswire
20 September 2021
PrEP science

One dose of TAF every three days gets more drug into cells than a daily dose of TDF

News
17 September 2021
Starting treatment

Dolutegravir more likely to suppress very high viral loads than other recommended first-line drugs

News
14 September 2021
PrEP science

First-in-Class NRTTI Demonstrates Potential as Long-Acting Oral PrEP Against HIV

Editor's pick
Contagion Live
13 September 2021
PrEP science

Truvada or Descovy for PrEP? Your Lab Work May Tell You

Editor's pick
POZ
8 September 2021
Clinical trials

Treatment interruption in cure research is associated with greater risk of non-AIDS related events in the long term, Spanish study finds

News
7 September 2021
Adherence

Dolutegravir-based regimens result in sustained viral suppression, despite lower adherence and treatment interruptions

News
20 August 2021
New & experimental HIV treatments

CytoDyn’s previous HIV filing snafu now on better course after FDA sets them straight

Editor's pick
Fierce Biotech
16 August 2021
Resistance

Transmitted Drug Resistance to Tenofovir and Emtricitabine is declining in China

Editor's pick
Infectious Disease Advisor
12 August 2021
Pharmaceutical industry

Negative innovation: when patents are bad for patients

Editor's pick
Nature
12 August 2021
Injectable & long-acting HIV treatment

New Guideline for Replacement ART: CAB/RPV LA Not for Everyone

Editor's pick
Medscape (requires free registration)
3 August 2021
Injectable & long-acting HIV treatment

A Change of Pace

Editor's pick
POZ
2 August 2021
Access to healthcare

Pricing agreement brings HIV drug darunavir within reach of LMICs

Editor's pick
Devex
29 July 2021
Antibody-based prevention

HIV vaccines and immunotherapies “would be further along” if they had the resources of COVID-19, says leading antibody researcher

News
28 July 2021
Injectable & long-acting HIV treatment

Failed viral suppression in CAB/RPV linked to 3 Risk Factors

Editor's pick
Medscape (requires free registration)
28 July 2021